Pharmaceutical Executive
With Spain now squarely on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top-tier investment destination once more.
With Spain now squarely on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top-tier investment destination once more thanks to a much improved market access scenario, high quality but affordable manufacturing capabilities, and an enviable clinical research base. Gone are many of the forced price reductions and ejections from the reimbursement list that coincided with the implementation of successive austerity programs. Instead, Spain today stands proud as the tenth-largest pharma market in the world, with a valuation of EUR 26.15 billion (USD 29.55 billion) in 2017, according to BMI.
“Overall the Spanish life sciences sector has exhibited great resilience, having initially endured quite a hammering: for the past three years, the overall value of pharmaceutical sales in the hospital segment expanded at a rate of 3.3% while retail sales increased 2.2%... I genuinely cannot think of any other European market that has enjoyed an analogous growth trajectory,” concedes Humberto Arnés, the director general of Farmaindustria, Spain’s leading pharmaceutical industry association.
A visible improvement to the market access context has naturally been a decisive factor in this turnaround in investor confidence. “In addition to market growth, two other important indicators reflect positive change: product availability and the timeframe taken for a product approved by the EMA to reach the Spanish market,” explains Arnés. “We had dramatically dropped behind for both indicators during the crisis, but are thankfully now back in line with markets such as Italy, France, and Germany.”
To view the full article on Spain's pharmaceutical and healthcare markets, produced by Focus Reports and featured in Pharm Exec's February 2019 issue, click
here(cycle down to page 24).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.